JP7325928B2 - 改善された免疫グロブリン可変ドメイン - Google Patents
改善された免疫グロブリン可変ドメイン Download PDFInfo
- Publication number
- JP7325928B2 JP7325928B2 JP2017512424A JP2017512424A JP7325928B2 JP 7325928 B2 JP7325928 B2 JP 7325928B2 JP 2017512424 A JP2017512424 A JP 2017512424A JP 2017512424 A JP2017512424 A JP 2017512424A JP 7325928 B2 JP7325928 B2 JP 7325928B2
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- acid residue
- domains
- heavy chain
- residue
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 108060003951 Immunoglobulin Proteins 0.000 title claims description 86
- 102000018358 immunoglobulin Human genes 0.000 title claims description 86
- 125000000539 amino acid group Chemical group 0.000 claims description 814
- 108010003723 Single-Domain Antibodies Proteins 0.000 claims description 293
- 210000004899 c-terminal region Anatomy 0.000 claims description 278
- 230000027455 binding Effects 0.000 claims description 247
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 158
- 235000004279 alanine Nutrition 0.000 claims description 152
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 146
- 235000001014 amino acid Nutrition 0.000 claims description 143
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 142
- 229920001184 polypeptide Polymers 0.000 claims description 139
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 136
- 229940024606 amino acid Drugs 0.000 claims description 136
- 150000001413 amino acids Chemical group 0.000 claims description 92
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 claims description 80
- 239000004471 Glycine Substances 0.000 claims description 75
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 72
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 72
- 229910052700 potassium Inorganic materials 0.000 claims description 63
- 102000008100 Human Serum Albumin Human genes 0.000 claims description 53
- 108091006905 Human Serum Albumin Proteins 0.000 claims description 53
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims description 44
- 239000000427 antigen Substances 0.000 claims description 43
- 102000036639 antigens Human genes 0.000 claims description 40
- 108091007433 antigens Proteins 0.000 claims description 40
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 37
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims description 37
- 239000004474 valine Substances 0.000 claims description 37
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims description 36
- 229960000310 isoleucine Drugs 0.000 claims description 36
- 241000282412 Homo Species 0.000 claims description 34
- 238000000034 method Methods 0.000 claims description 27
- 150000007523 nucleic acids Chemical group 0.000 claims description 14
- 239000008194 pharmaceutical composition Substances 0.000 claims description 13
- 108020004707 nucleic acids Proteins 0.000 claims description 11
- 102000039446 nucleic acids Human genes 0.000 claims description 11
- 230000003993 interaction Effects 0.000 claims description 6
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 description 309
- 125000003275 alpha amino acid group Chemical group 0.000 description 177
- 108090000623 proteins and genes Proteins 0.000 description 134
- 235000018102 proteins Nutrition 0.000 description 132
- 102000004169 proteins and genes Human genes 0.000 description 132
- 102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 description 111
- 101001057612 Homo sapiens Dual specificity protein phosphatase 5 Proteins 0.000 description 106
- 102000043381 human DUSP5 Human genes 0.000 description 106
- 102000007562 Serum Albumin Human genes 0.000 description 104
- 108010071390 Serum Albumin Proteins 0.000 description 104
- 230000035772 mutation Effects 0.000 description 90
- 238000006467 substitution reaction Methods 0.000 description 89
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 71
- 239000004473 Threonine Substances 0.000 description 71
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 63
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 62
- 101100112922 Candida albicans CDR3 gene Proteins 0.000 description 53
- 102100035361 Cerebellar degeneration-related protein 2 Human genes 0.000 description 49
- 101000737796 Homo sapiens Cerebellar degeneration-related protein 2 Proteins 0.000 description 49
- 102200058105 rs63750815 Human genes 0.000 description 44
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 39
- 235000013922 glutamic acid Nutrition 0.000 description 39
- 239000004220 glutamic acid Substances 0.000 description 39
- 102220041913 rs587780812 Human genes 0.000 description 39
- 210000002966 serum Anatomy 0.000 description 39
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 36
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 31
- 101800001718 Amyloid-beta protein Proteins 0.000 description 30
- 235000002198 Annona diversifolia Nutrition 0.000 description 28
- 102100031650 C-X-C chemokine receptor type 4 Human genes 0.000 description 28
- 101710082513 C-X-C chemokine receptor type 4 Proteins 0.000 description 28
- 241000282838 Lama Species 0.000 description 28
- 102100022716 Atypical chemokine receptor 3 Human genes 0.000 description 26
- 108050008792 Atypical chemokine receptor 3 Proteins 0.000 description 26
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 25
- 230000001225 therapeutic effect Effects 0.000 description 25
- 230000009977 dual effect Effects 0.000 description 23
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 21
- 101000693967 Trachemys scripta 67 kDa serum albumin Proteins 0.000 description 17
- 102000004506 Blood Proteins Human genes 0.000 description 16
- 108010017384 Blood Proteins Proteins 0.000 description 16
- 201000010099 disease Diseases 0.000 description 16
- 210000004369 blood Anatomy 0.000 description 15
- 239000008280 blood Substances 0.000 description 15
- 208000035475 disorder Diseases 0.000 description 15
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 description 14
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 description 14
- 238000012360 testing method Methods 0.000 description 13
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 9
- 239000004472 Lysine Substances 0.000 description 9
- 229960000074 biopharmaceutical Drugs 0.000 description 9
- 239000000126 substance Substances 0.000 description 9
- 101000611441 Solanum lycopersicum Pathogenesis-related leaf protein 6 Proteins 0.000 description 8
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 8
- 102220274086 rs1379627026 Human genes 0.000 description 8
- 239000000523 sample Substances 0.000 description 7
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 208000026278 immune system disease Diseases 0.000 description 6
- 125000001433 C-terminal amino-acid group Chemical group 0.000 description 5
- 230000002209 hydrophobic effect Effects 0.000 description 5
- 102220091529 rs148370267 Human genes 0.000 description 5
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 4
- 102000009027 Albumins Human genes 0.000 description 4
- 108010088751 Albumins Proteins 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 238000007306 functionalization reaction Methods 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 4
- 208000023275 Autoimmune disease Diseases 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 3
- 101000737793 Homo sapiens Cerebellar degeneration-related antigen 1 Proteins 0.000 description 3
- 210000003719 b-lymphocyte Anatomy 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- 150000005829 chemical entities Chemical class 0.000 description 3
- 206010012601 diabetes mellitus Diseases 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 238000012552 review Methods 0.000 description 3
- 206010039073 rheumatoid arthritis Diseases 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 241000282832 Camelidae Species 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- 230000009824 affinity maturation Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000003124 biologic agent Substances 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 238000010494 dissociation reaction Methods 0.000 description 2
- 230000005593 dissociations Effects 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 210000004602 germ cell Anatomy 0.000 description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 102220087976 rs766022243 Human genes 0.000 description 2
- 230000001568 sexual effect Effects 0.000 description 2
- 241000894007 species Species 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- AETVBWZVKDOWHH-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]-3-(1-ethylazetidin-3-yl)oxypyrazol-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C=1C(=NN(C=1)CC(=O)N1CC2=C(CC1)NN=N2)OC1CN(C1)CC AETVBWZVKDOWHH-UHFFFAOYSA-N 0.000 description 1
- PMUNIMVZCACZBB-UHFFFAOYSA-N 2-hydroxyethylazanium;chloride Chemical compound Cl.NCCO PMUNIMVZCACZBB-UHFFFAOYSA-N 0.000 description 1
- 102220612213 Calcyclin-binding protein_E1D_mutation Human genes 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 102220553770 Cyclic GMP-AMP synthase_K83R_mutation Human genes 0.000 description 1
- 102220553650 Cyclic GMP-AMP synthase_T97E_mutation Human genes 0.000 description 1
- 101150105462 HIS6 gene Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 101100395023 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) his-7 gene Proteins 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 102220528594 Ribonuclease P/MRP protein subunit POP5_M53A_mutation Human genes 0.000 description 1
- 102220570985 Uncharacterized protein C7orf57_A74S_mutation Human genes 0.000 description 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 238000012867 alanine scanning Methods 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 208000037765 diseases and disorders Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 1
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 229940125425 inverse agonist Drugs 0.000 description 1
- 125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 230000006320 pegylation Effects 0.000 description 1
- 238000002823 phage display Methods 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 238000002818 protein evolution Methods 0.000 description 1
- 238000002708 random mutagenesis Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000002702 ribosome display Methods 0.000 description 1
- 102200086452 rs2230351 Human genes 0.000 description 1
- 102220028415 rs386352302 Human genes 0.000 description 1
- 102220034070 rs61753983 Human genes 0.000 description 1
- 102200133317 rs869025586 Human genes 0.000 description 1
- 239000012146 running buffer Substances 0.000 description 1
- 230000009919 sequestration Effects 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 102100036537 von Willebrand factor Human genes 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
- C07K16/4283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
- C07K16/4291—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig against IgE
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B40/00—Libraries per se, e.g. arrays, mixtures
- C40B40/04—Libraries containing only organic compounds
- C40B40/10—Libraries containing peptides or polypeptides, or derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/35—Valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Cell Biology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021087053A JP7454525B2 (ja) | 2014-05-16 | 2021-05-24 | 改善された免疫グロブリン可変ドメイン |
| JP2024037026A JP2024069377A (ja) | 2014-05-16 | 2024-03-11 | 改善された免疫グロブリン可変ドメイン |
Applications Claiming Priority (12)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461994552P | 2014-05-16 | 2014-05-16 | |
| US61/994,552 | 2014-05-16 | ||
| US201461014015P | 2014-06-18 | 2014-06-18 | |
| US201462014015P | 2014-06-18 | 2014-06-18 | |
| US62/014,015 | 2014-06-18 | ||
| US201462040167P | 2014-08-21 | 2014-08-21 | |
| US62/040,167 | 2014-08-21 | ||
| US201462047560P | 2014-09-08 | 2014-09-08 | |
| US62/047,560 | 2014-09-08 | ||
| US201562133600P | 2015-03-16 | 2015-03-16 | |
| US62/133,600 | 2015-03-16 | ||
| PCT/EP2015/060643 WO2015173325A2 (en) | 2014-05-16 | 2015-05-13 | Improved immunoglobulin variable domains |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018122878A Division JP7098439B2 (ja) | 2014-05-16 | 2018-06-28 | 改善された免疫グロブリン可変ドメイン |
| JP2021087053A Division JP7454525B2 (ja) | 2014-05-16 | 2021-05-24 | 改善された免疫グロブリン可変ドメイン |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017518072A JP2017518072A (ja) | 2017-07-06 |
| JP2017518072A5 JP2017518072A5 (enExample) | 2018-06-21 |
| JP7325928B2 true JP7325928B2 (ja) | 2023-08-15 |
Family
ID=91193230
Family Applications (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017512424A Active JP7325928B2 (ja) | 2014-05-16 | 2015-05-13 | 改善された免疫グロブリン可変ドメイン |
| JP2018122878A Active JP7098439B2 (ja) | 2014-05-16 | 2018-06-28 | 改善された免疫グロブリン可変ドメイン |
| JP2020167247A Active JP7471987B2 (ja) | 2014-05-16 | 2020-10-01 | 改善された免疫グロブリン可変ドメイン |
| JP2021087053A Active JP7454525B2 (ja) | 2014-05-16 | 2021-05-24 | 改善された免疫グロブリン可変ドメイン |
| JP2024004779A Pending JP2024041939A (ja) | 2014-05-16 | 2024-01-16 | 改善された免疫グロブリン可変ドメイン |
| JP2024037026A Pending JP2024069377A (ja) | 2014-05-16 | 2024-03-11 | 改善された免疫グロブリン可変ドメイン |
Family Applications After (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018122878A Active JP7098439B2 (ja) | 2014-05-16 | 2018-06-28 | 改善された免疫グロブリン可変ドメイン |
| JP2020167247A Active JP7471987B2 (ja) | 2014-05-16 | 2020-10-01 | 改善された免疫グロブリン可変ドメイン |
| JP2021087053A Active JP7454525B2 (ja) | 2014-05-16 | 2021-05-24 | 改善された免疫グロブリン可変ドメイン |
| JP2024004779A Pending JP2024041939A (ja) | 2014-05-16 | 2024-01-16 | 改善された免疫グロブリン可変ドメイン |
| JP2024037026A Pending JP2024069377A (ja) | 2014-05-16 | 2024-03-11 | 改善された免疫グロブリン可変ドメイン |
Country Status (25)
| Country | Link |
|---|---|
| US (10) | US12180268B2 (enExample) |
| EP (4) | EP3702369A1 (enExample) |
| JP (6) | JP7325928B2 (enExample) |
| KR (5) | KR102769509B1 (enExample) |
| CN (3) | CN106661100A (enExample) |
| AU (6) | AU2015261536B2 (enExample) |
| BR (2) | BR112016026773A2 (enExample) |
| CA (2) | CA2948076A1 (enExample) |
| DK (2) | DK3248986T3 (enExample) |
| ES (2) | ES2815572T3 (enExample) |
| HR (2) | HRP20200966T1 (enExample) |
| HU (2) | HUE050007T2 (enExample) |
| IL (6) | IL295534B2 (enExample) |
| LT (2) | LT3248986T (enExample) |
| MX (4) | MX383560B (enExample) |
| NZ (1) | NZ726448A (enExample) |
| PH (1) | PH12016502282B1 (enExample) |
| PL (2) | PL3248986T3 (enExample) |
| PT (2) | PT3248986T (enExample) |
| RS (2) | RS63085B1 (enExample) |
| RU (1) | RU2746738C2 (enExample) |
| SG (3) | SG11201609162SA (enExample) |
| SI (2) | SI3248986T1 (enExample) |
| WO (1) | WO2015173325A2 (enExample) |
| ZA (5) | ZA201607587B (enExample) |
Families Citing this family (87)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11644471B2 (en) | 2010-09-30 | 2023-05-09 | Ablynx N.V. | Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains |
| AU2012273929B2 (en) | 2011-06-23 | 2017-04-27 | Ablynx Nv | Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains |
| CN106661100A (zh) | 2014-05-16 | 2017-05-10 | 埃博灵克斯股份有限公司 | 改进的免疫球蛋白可变结构域 |
| IL318433A (en) | 2014-05-16 | 2025-03-01 | Ablynx Nv | Improved immunoglobulin variable complexes |
| CN107531777A (zh) | 2015-01-21 | 2018-01-02 | 英伊布里克斯有限合伙公司 | 非免疫原性单结构域抗体 |
| NO2768984T3 (enExample) * | 2015-11-12 | 2018-06-09 | ||
| AU2016352695B2 (en) * | 2015-11-12 | 2023-07-27 | Ablynx Nv | Improved P2X7 receptor binders and polypeptides comprising the same |
| HRP20220080T1 (hr) * | 2015-11-13 | 2022-04-15 | Ablynx N.V. | Poboljšane imunoglobulinske varijabilne domene koje vežu serumski albumin |
| JO3739B1 (ar) * | 2015-11-18 | 2021-01-31 | Merck Sharp & Dohme | روابط ctla4 |
| AU2016357460B2 (en) * | 2015-11-18 | 2023-07-27 | Ablynx Nv | Improved serum albumin binders |
| IL300122A (en) | 2015-11-18 | 2023-03-01 | Merck Sharp ַ& Dohme Llc | Substances that bind to PD1 and/or LAG3 |
| AU2016355568A1 (en) | 2015-11-18 | 2018-06-21 | Merck Sharp & Dohme Llc | PD1/CTLA4 Binders |
| CA3014443A1 (en) | 2016-02-12 | 2017-08-17 | Ablynx Nv | Method for the production of immunoglobulin single variable domains |
| CN107400166A (zh) * | 2016-05-19 | 2017-11-28 | 苏州康宁杰瑞生物科技有限公司 | 针对ctla4的单域抗体及其衍生蛋白 |
| JP7150618B2 (ja) | 2016-06-23 | 2022-10-11 | アブリンクス エン．ヴェー． | 免疫グロブリン単一可変ドメインについての改善された薬物動態アッセイ |
| JP7222888B2 (ja) | 2016-11-16 | 2023-02-15 | アブリンクス エン．ヴェー． | Ｃｄ１２３及びｔｃｒアルファ／ベータに結合することが可能なｔ細胞動員ポリペプチド |
| AU2017373746B2 (en) * | 2016-12-07 | 2024-11-14 | Ablynx Nv | Improved serum albumin binding immunoglobulin single variable domains |
| KR20230165374A (ko) | 2017-01-17 | 2023-12-05 | 아블린쓰 엔.브이. | 개선된 혈청 알부민 결합제 |
| MX2019008496A (es) | 2017-01-17 | 2019-09-18 | Ablynx Nv | Aglutinantes de albumina serica mejorados. |
| KR20250011229A (ko) | 2017-06-02 | 2025-01-21 | 메르크 파텐트 게엠베하 | Adamts 결합성 면역글로불린 |
| WO2019016237A1 (en) | 2017-07-19 | 2019-01-24 | Vib Vzw | AGENTS FOR CONNECTING TO SERUM ALBUMIN |
| CA3076791A1 (en) | 2017-10-31 | 2019-05-09 | Vib Vzw | Novel antigen-binding chimeric proteins and methods and uses thereof |
| WO2020176478A1 (en) | 2019-02-25 | 2020-09-03 | The University Of Chicago | Methods and compositions for treating inflammatory and autoimmune conditions with ecm-affinity peptides linked to anti-inflammatory agents |
| WO2020221888A1 (en) | 2019-04-30 | 2020-11-05 | Vib Vzw | Cystic fibrosis transmembrane conductance regulator stabilizing agents |
| CA3158991A1 (en) | 2019-11-27 | 2021-06-03 | Vib Vzw | Positive allosteric modulators of the calcium-sensing receptor |
| WO2021110816A1 (en) | 2019-12-06 | 2021-06-10 | Ablynx Nv | POLYPEPTIDES COMPRISING IMMUNOGLOBULIN SINGLE VARIABLE DOMAINS TARGETING TNFα AND IL-23 |
| MX2022006881A (es) | 2019-12-06 | 2022-07-11 | Ablynx Nv | Polipeptidos que comprenden dominios variables unicos de inmunoglobulina dirigidos a tnf alfa y ox40l. |
| TW202530257A (zh) | 2019-12-09 | 2025-08-01 | 比利時商艾伯霖克斯公司 | 包含靶向il-13及tslp之免疫球蛋白單可變域的多肽 |
| AR120698A1 (es) | 2019-12-09 | 2022-03-09 | Ablynx Nv | Polipéptidos que comprenden dominios variables únicos de inmunoglobulina que se dirigen a il-13 y tslp |
| WO2021123360A1 (en) | 2019-12-20 | 2021-06-24 | Vib Vzw | Nanobody exchange chromatography |
| WO2021156490A2 (en) | 2020-02-06 | 2021-08-12 | Vib Vzw | Corona virus binders |
| KR20230012464A (ko) | 2020-02-25 | 2023-01-26 | 브이아이비 브이지더블유 | 류신-풍부 반복 키나제 2 알로스테릭 조절제 |
| CA3175873A1 (en) | 2020-03-30 | 2021-10-07 | Ablynx Nv | Method for the production and purification of multivalent immunoglobulin single variable domains |
| WO2022003156A1 (en) | 2020-07-02 | 2022-01-06 | Oncurious Nv | Ccr8 non-blocking binders |
| CA3190415A1 (en) * | 2020-08-05 | 2022-02-10 | Synthekine, Inc. | Il2rb/il2rg synthetic cytokines |
| WO2022063984A1 (en) | 2020-09-25 | 2022-03-31 | Ablynx Nv | Polypeptides comprising immunoglobulin single variable domains targeting il-13 and ox40l |
| US20240018248A1 (en) | 2020-12-02 | 2024-01-18 | Vib Vzw | An ltbr agonist in combination therapy against cancer |
| WO2022117569A1 (en) | 2020-12-02 | 2022-06-09 | Oncurious Nv | A ccr8 antagonist antibody in combination with a lymphotoxin beta receptor agonist antibody in therapy against cancer |
| PH12023500013A1 (en) | 2020-12-04 | 2024-03-11 | Tidal Therapeutics Inc | Ionizable cationic lipids and lipi nanoparticles, and methods of synthesis and use thereof |
| TW202241947A (zh) | 2020-12-18 | 2022-11-01 | 比利時商艾伯霖克斯公司 | 包含靶向磷脂醯肌醇蛋白聚糖—３和ｔ細胞受體的免疫球蛋白單可變結構域的多肽 |
| KR20230122084A (ko) | 2020-12-18 | 2023-08-22 | 아블린쓰 엔.브이. | Tcr 알파/베타 반응성에 기초한 t 세포 동원 폴리펩타이드 |
| WO2022129572A1 (en) | 2020-12-18 | 2022-06-23 | Ablynx Nv | Polypeptides comprising immunoglobulin single variable domains targeting il-6 and tnf-alpha |
| GB202020502D0 (en) | 2020-12-23 | 2021-02-03 | Vib Vzw | Antibody composistion for treatment of corona virus infection |
| JP2024506020A (ja) | 2021-02-05 | 2024-02-08 | ブイアイビー ブイゼットダブリュ | サルベコウイルス結合剤 |
| CN117794566A (zh) | 2021-02-05 | 2024-03-29 | Vib研究所 | 沙贝病毒结合剂 |
| US20250263490A1 (en) | 2021-02-19 | 2025-08-21 | Vib Vzw | Cation-Independent Mannose-6-Phosphate Receptor Binders |
| WO2022206900A1 (zh) * | 2021-04-01 | 2022-10-06 | 江苏先声药业有限公司 | 抗人血清白蛋白(hsa)的纳米抗体及其应用 |
| JP2024530455A (ja) | 2021-07-30 | 2024-08-21 | ブイアイビー ブイゼットダブリュ | 標的化タンパク質の分解のためのカチオン非依存性マンノース６リン酸受容体結合体 |
| CN118339179A (zh) * | 2021-11-29 | 2024-07-12 | 江苏恒瑞医药股份有限公司 | 经修饰的蛋白或多肽 |
| AU2022409733A1 (en) | 2021-12-17 | 2024-08-01 | Ablynx Nv | POLYPEPTIDES COMPRISING IMMUNOGLOBULIN SINGLE VARIABLE DOMAINS TARGETING TCRαβ, CD33 AND CD123 |
| WO2023135198A1 (en) | 2022-01-12 | 2023-07-20 | Vib Vzw | Human ntcp binders for therapeutic use and liver-specific targeted delivery |
| WO2023198848A1 (en) | 2022-04-13 | 2023-10-19 | Vib Vzw | An ltbr agonist in combination therapy against cancer |
| EP4273162A1 (en) * | 2022-05-06 | 2023-11-08 | Numab Therapeutics AG | Antibody variable domains and antibodies having decreased immunogenicity |
| KR20250008754A (ko) | 2022-05-06 | 2025-01-15 | 누맙 세러퓨틱스 아게 | 면역원성이 감소된 항체 가변 도메인 및 항체 |
| US20250313611A1 (en) | 2022-05-18 | 2025-10-09 | Vib Vzw | Sarbecovirus spike s2 subunit binders |
| IL317461A (en) | 2022-06-08 | 2025-02-01 | Tidal Therapeutics Inc | Ionized Cationic Lipids and Lipid Nanoparticles and Methods of Synthesis and Use thereof |
| KR20250023503A (ko) | 2022-06-14 | 2025-02-18 | 아블린쓰 | T 세포 수용체를 표적화하는 면역글로불린 단일 가변 도메인 |
| KR20250042176A (ko) | 2022-07-27 | 2025-03-26 | 아블린쓰 | 신생아 fc 수용체의 특정 에피토프에 결합하는 폴리펩타이드 |
| WO2024068744A1 (en) | 2022-09-27 | 2024-04-04 | Vib Vzw | Antivirals against human parainfluenza virus |
| EP4605077A1 (en) | 2022-10-18 | 2025-08-27 | Confo Therapeutics N.V. | Amino acid sequences directed against the melanocortin 4 receptor and polypeptides comprising the same for the treatment of mc4r-related diseases and disorders |
| IL321639A (en) | 2022-12-21 | 2025-08-01 | Genzyme Corp | Anti pd 1×4 1bb binding proteins |
| WO2024133935A1 (en) | 2022-12-23 | 2024-06-27 | Ablynx Nv | Protein-based conjugation carriers |
| WO2024151515A2 (en) | 2023-01-09 | 2024-07-18 | Odyssey Therapeutics, Inc. | Anti-tnfr2 antigen-binding proteins and uses thereof |
| EP4646272A2 (en) | 2023-02-10 | 2025-11-12 | Amunix Pharmaceuticals, Inc. | Compositions targeting prostate-specific membrane antigen (psma) and methods for making and using the same |
| CN120712282A (zh) | 2023-02-17 | 2025-09-26 | 阿布林克斯有限公司 | 结合新生儿fc受体的多肽 |
| WO2024175787A1 (en) | 2023-02-24 | 2024-08-29 | Vrije Universiteit Brussel | Anti-inflammatory pannexin 1 channel inhibitors |
| AU2024234615A1 (en) | 2023-03-14 | 2025-08-21 | Odyssey Therapeutics, Inc. | Anti-cd25 antigen-binding proteins and uses thereof |
| WO2024208816A1 (en) | 2023-04-03 | 2024-10-10 | Vib Vzw | Blood-brain barrier crossing antibodies |
| TW202509060A (zh) | 2023-05-08 | 2025-03-01 | 法商賽諾菲公司 | 免疫球蛋白單可變結構域的醣基化 |
| WO2024238790A1 (en) | 2023-05-17 | 2024-11-21 | Odyssey Therapeutics, Inc. | Modified single-domain antibodies |
| WO2024261235A1 (en) | 2023-06-22 | 2024-12-26 | Ablynx Nv | Chimeric proteins for modulating cytokine receptor activity |
| AU2024308381A1 (en) | 2023-06-29 | 2025-11-20 | Odyssey Therapeutics, Inc. | Anti-trailr2 antigen-binding proteins and uses thereof |
| US20250034260A1 (en) | 2023-07-05 | 2025-01-30 | Sanofi | Fcrn antagonists for treatment of igg-related diseases and disorders |
| WO2025051767A1 (en) | 2023-09-04 | 2025-03-13 | Sanofi | Polypeptides for use in the treatment of glypican-3-expressing tumours |
| TW202532432A (zh) | 2023-09-22 | 2025-08-16 | 比利時商艾伯霖克斯公司 | 二及多價白蛋白結合劑 |
| TW202530265A (zh) | 2023-10-13 | 2025-08-01 | 美商奧迪希治療公司 | 抗cdh17抗原結合蛋白及其用途 |
| WO2025099632A1 (en) | 2023-11-08 | 2025-05-15 | Sanofi | Cd25 based lysosomal degrader and uses thereof |
| WO2025109176A1 (en) | 2023-11-22 | 2025-05-30 | Exevir Bio Bv | Optimized sarbecovirus spike s2 subunit binders and compositions comprising the same |
| US20250296991A1 (en) | 2023-12-01 | 2025-09-25 | Ablynx N.V. | Precision activated polypeptides |
| WO2025125577A1 (en) | 2023-12-14 | 2025-06-19 | Vib Vzw | Antibodies against influenza b virus |
| US20250236673A1 (en) | 2023-12-22 | 2025-07-24 | Ablynx N.V. | Protein-based carriers for site-specific amine conjugation |
| WO2025133253A2 (en) | 2023-12-22 | 2025-06-26 | Ablynx Nv | Protein-based conjugation carriers for intranuclear delivery |
| WO2025174825A2 (en) | 2024-02-12 | 2025-08-21 | Aera Therapeutics, Inc. | Delivery compositions |
| WO2025181155A1 (en) | 2024-02-26 | 2025-09-04 | Vib Vzw | Human beta-glucocerebrosidase binders and uses thereof |
| WO2025217240A1 (en) | 2024-04-10 | 2025-10-16 | Odyssey Therapeutics, Inc. | Anti-tnfr2 antigen-binding proteins and uses thereof |
| US12459994B2 (en) | 2024-04-12 | 2025-11-04 | Paragon Therapeutics, Inc. | Albumin binding proteins and methods of use |
| WO2025219231A1 (en) | 2024-04-15 | 2025-10-23 | Vib Vzw | Computer-implemented means and methods for the de novo design of antibodies targeting a specific epitope |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005092925A2 (en) | 2004-03-24 | 2005-10-06 | Xencor, Inc. | Immunoglobulin variants outside the fc region |
| JP2012500006A (ja) | 2008-08-11 | 2012-01-05 | メダレックス インコーポレーティッド | リンパ球活性化遺伝子−３（ｌａｇ−３）へ結合するヒト抗体およびその使用 |
| JP5047950B2 (ja) | 2005-05-18 | 2012-10-10 | アブリンクス エン．ヴェー． | 腫瘍壊死因子−アルファに対する改良ナノボディ（商標） |
| WO2012156219A1 (en) | 2011-05-05 | 2012-11-22 | Ablynx Nv | Amino acid sequences directed against il-17a, il-17f and/or il17-a/f and polypeptides comprising the same |
| WO2012175741A2 (en) | 2011-06-23 | 2012-12-27 | Ablynx Nv | Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains |
| WO2013024059A2 (en) | 2011-08-17 | 2013-02-21 | Glaxo Group Limited | Modified proteins and peptides |
| WO2014004427A2 (en) | 2012-06-25 | 2014-01-03 | Regeneron Pharmaceuticals, Inc. | Anti-egfr antibodies and uses thereof |
Family Cites Families (89)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1545106C3 (de) * | 1963-07-16 | 1979-05-31 | Union Carbide Corp., New York, N.Y. (V.St.A.) | Verfahren zur Herstellung von linearen Polyarylenpolyäthern |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| JP3101690B2 (ja) | 1987-03-18 | 2000-10-23 | エス・ビィ・２・インコーポレイテッド | 変性抗体の、または変性抗体に関する改良 |
| US5028608A (en) | 1989-12-11 | 1991-07-02 | The Trustees Of Princeton University | N-(6-Amino-(pyrrolo(2,3-d)pyrimidin-3-ylacyl) )-glutamic acid derivatives |
| US5248775A (en) | 1989-12-11 | 1993-09-28 | The Trustees Of Princeton University | Pyrrolo(2,3-d)pyrimidines |
| KR0162654B1 (ko) | 1989-12-11 | 1998-11-16 | 알렌 제이. 시니스갤리 | N-(피롤로[2,3-d]피리미딘-3-일아크릴)-글루타민산 유도체 |
| JP4124480B2 (ja) | 1991-06-14 | 2008-07-23 | ジェネンテック・インコーポレーテッド | 免疫グロブリン変異体 |
| DE69330523T4 (de) | 1992-08-21 | 2012-08-23 | Vrije Universiteit Brussel | Immunoglobuline ohne leichte ketten |
| US20020155604A1 (en) | 1998-02-19 | 2002-10-24 | Jeffrey A. Ledbetter | Compositions and methods for regulating lymphocyte activation |
| KR20060067983A (ko) | 1999-01-15 | 2006-06-20 | 제넨테크, 인크. | 효과기 기능이 변화된 폴리펩티드 변이체 |
| WO2002057445A1 (en) * | 2000-05-26 | 2002-07-25 | National Research Council Of Canada | Single-domain brain-targeting antibody fragments derived from llama antibodies |
| US7829084B2 (en) | 2001-01-17 | 2010-11-09 | Trubion Pharmaceuticals, Inc. | Binding constructs and methods for use thereof |
| US20100081792A1 (en) | 2001-06-28 | 2010-04-01 | Smithkline Beecham Corporation | Ligand |
| CN1642982A (zh) | 2001-07-26 | 2005-07-20 | 唐诚公司 | 活化或抑制类Toll受体9的试剂 |
| JP2005289809A (ja) | 2001-10-24 | 2005-10-20 | Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw) | 突然変異重鎖抗体 |
| CA2492092A1 (en) | 2002-06-28 | 2004-01-08 | Greg Winter | Immunoglobin single variant antigen-binding domains and dual-specific constructs |
| US20060002935A1 (en) | 2002-06-28 | 2006-01-05 | Domantis Limited | Tumor Necrosis Factor Receptor 1 antagonists and methods of use therefor |
| US9321832B2 (en) | 2002-06-28 | 2016-04-26 | Domantis Limited | Ligand |
| FR2846667B1 (fr) | 2002-11-06 | 2004-12-31 | Pasteur Institut | Fragments variables d'anticorps de camelides a chaine unique diriges contre le peptide beta-amyloide 1-42 et leurs applications pour le diagnostic et le traitement des maladies neuroagregatives |
| AU2003286002B2 (en) | 2002-11-08 | 2011-06-16 | Ablynx N.V. | Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor |
| CA2505325C (en) | 2002-11-08 | 2014-02-25 | Ablynx N.V. | Stabilized single domain antibodies |
| GB0230203D0 (en) | 2002-12-27 | 2003-02-05 | Domantis Ltd | Fc fusion |
| KR20080113286A (ko) | 2003-01-10 | 2008-12-29 | 아블린쓰 엔.브이. | 폰 빌레브란트 인자(ｖＷＦ) 또는 콜라겐에 대한 낙타과로부터의 재조합 ＶＨＨ 단일 도메인 항체 |
| JP2008500830A (ja) | 2004-06-01 | 2008-01-17 | ドマンティス リミテッド | 増加した血清半減期を有する二重特異性融合抗体 |
| CA2583017A1 (en) | 2004-10-13 | 2006-04-20 | Ablynx N.V. | Single domain camelide anti-amyloid beta antibodies and polypeptides comprising the same for the treatment and diagnosis of degenerative neural diseases such as alzheimer's disease |
| KR20070094909A (ko) | 2004-12-02 | 2007-09-27 | 도만티스 리미티드 | 혈청 알부민 및 ｇｌｐ-1 또는 ｐｙｙ를 표적으로 삼는이중특이성 도메인을 갖는 항체 |
| CA2588892A1 (en) | 2004-12-02 | 2006-06-08 | Dormantis Limited | Anti-il-1r1 single domain antibodies and therapeutic uses |
| CN101213214B (zh) | 2005-05-20 | 2014-06-25 | 埃博灵克斯股份有限公司 | 针对冯威勒布兰特因子的单一结构域vhh抗体 |
| WO2006129843A2 (en) | 2005-05-31 | 2006-12-07 | Canon Kabushiki Kaisha | Bispecific capturing molecule |
| PE20071101A1 (es) * | 2005-08-31 | 2007-12-21 | Amgen Inc | Polipeptidos y anticuerpos |
| EA200801170A1 (ru) | 2005-12-01 | 2008-12-30 | Домантис Лимитед | Форматы неконкурентного доменного антитела, которые связываются с рецептором интерлейкина 1 первого типа |
| KR20080077237A (ko) | 2005-12-01 | 2008-08-21 | 도만티스 리미티드 | 인터루킨 1 수용체 타입 1에 결합하는 경쟁적 도메인 항체포맷 |
| FR2894741B1 (fr) | 2005-12-08 | 2009-12-04 | Centre Nat Etd Spatiales | Chaine de reception par satellite |
| CA2640066A1 (en) | 2006-01-24 | 2007-08-02 | Roland Beckmann | Fusion proteins that contain natural junctions |
| CA2666599A1 (en) | 2006-08-18 | 2008-02-21 | Ablynx N.V. | Amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of diseases and disorders associated with il-6-mediated signalling |
| AU2007328900A1 (en) | 2006-12-05 | 2008-06-12 | Ablynx N.V. | Peptides capable of binding to serum proteins |
| CA2672595A1 (en) | 2006-12-15 | 2008-06-19 | Guy Hermans | Amino acid sequences that modulate the interaction between cells of the immune system |
| RU2481355C2 (ru) | 2007-05-24 | 2013-05-10 | Аблинкс Н.В. | Аминокислотные последовательности, направленные на rank-l, и полипептиды, включающие их, для лечения заболеваний и нарушений костей |
| EP2158315B1 (en) | 2007-06-25 | 2016-03-23 | ESBATech, an Alcon Biomedical Research Unit LLC | Methods of modifying antibodies, and modified antibodies with improved functional properties |
| WO2009068631A1 (en) | 2007-11-27 | 2009-06-04 | Ablynx N.V. | Method for obtaining polypeptide constructs comprising two or more single domain antibodies |
| MX2010010776A (es) | 2008-03-31 | 2010-10-26 | Glaxo Group Ltd | Fusiones y conjugados de farmaco. |
| US8217140B2 (en) | 2008-04-17 | 2012-07-10 | Ablynx N.V. | Peptides capable of binding to serum proteins and compounds, constructs and polypeptides comprising the same |
| WO2009138494A2 (en) * | 2008-05-15 | 2009-11-19 | Ablynx N.V. | Amino acid sequences directed against toll-like receptors and polypeptides comprising the same for the treatment of diseases related to toll-like receptors |
| DE102008023620A1 (de) | 2008-05-15 | 2009-11-19 | Mettler-Toledo (Albstadt) Gmbh | Funktionseinheit mit einer aufrufbaren Funktion und Verfahren zu deren Aufruf |
| US9212226B2 (en) | 2008-05-16 | 2015-12-15 | Ablynx N.V. | Amino acid sequences directed against CXCR4 and other GPCRs and compounds comprising the same |
| EP2143735A1 (en) * | 2008-07-10 | 2010-01-13 | Institut Pasteur | Variable domains of camelid heavy-chain antibodies directed against glial fibrillary acidic proteins |
| WO2010042815A2 (en) | 2008-10-09 | 2010-04-15 | Duke University | Vhh antibody fragments for use in the detection and treatment of cancer |
| EA021146B1 (ru) | 2009-03-27 | 2015-04-30 | Глаксо Груп Лимитед | Продукты слияния и конъюгаты лекарственных средств |
| DK2982690T3 (da) | 2009-04-30 | 2021-04-12 | Ablynx Nv | Fremgangsmåde til fremstilling af domæne-antistoffer |
| WO2010130832A2 (en) | 2009-05-15 | 2010-11-18 | Ablynx N.V. | Amino acid sequences directed against dickkopf-1 and polypeptides comprising the same for the treatment of diseases and disorders associated with bone loss and/or osteolytic lesions |
| US20120264917A1 (en) | 2009-05-27 | 2012-10-18 | Ablynx N.V. | Biparatopic protein constructs directed against il-23 |
| UY32665A (es) | 2009-05-28 | 2010-12-31 | Glaxo Group Ltd | Proteinas de union al antigeno |
| US9150640B2 (en) | 2009-07-10 | 2015-10-06 | Ablynx N.V. | Method for the production of variable domains |
| US8306355B2 (en) | 2009-07-13 | 2012-11-06 | Sharp Laboratories Of America, Inc. | Methods and systems for reducing compression artifacts |
| EP2486056A1 (en) | 2009-10-09 | 2012-08-15 | Ablynx N.V. | Immunoglobulin single variable domain directed against human cxcr4 and other cell associated proteins and methods to generate them |
| EP2513145B1 (en) | 2009-12-14 | 2018-01-24 | Ablynx N.V. | Single variable domain antibodies against ox40l, constructs and therapeutic use |
| WO2011075861A1 (en) * | 2009-12-23 | 2011-06-30 | Esbatech, An Alcon Biomedical Research Unit Llc | Method for decreasing immunogenicity |
| UY33253A (es) | 2010-03-03 | 2011-09-30 | Boehringer Ingelheim Int | Polipéptidos de unión a a-beta |
| WO2011117423A1 (en) | 2010-03-26 | 2011-09-29 | Ablynx N.V. | Immunoglobulin single variable domains directed against cxcr7 |
| CN102971341A (zh) | 2010-04-30 | 2013-03-13 | 埃博灵克斯股份有限公司 | 针对异二聚体细胞因子IL-23的p19亚基的纳米抗体的氨基酸序列 |
| PH12012502272A1 (en) | 2010-05-20 | 2017-07-26 | Ablynx Nv | Biological materials related to her3 |
| WO2011161266A1 (en) | 2010-06-25 | 2011-12-29 | Ablynx Nv | Improved immunoglobulin single variable domains and constructs thereof directed against cxcr4 |
| JP2013145769A (ja) | 2010-08-04 | 2013-07-25 | Kri Inc | 異方性希土類ボンド磁石とその製造方法 |
| EP2621953B1 (en) | 2010-09-30 | 2017-04-05 | Ablynx N.V. | Biological materials related to c-met |
| WO2012104227A1 (en) | 2011-02-02 | 2012-08-09 | Glaxo Group Limited | Novel antigen binding proteins |
| CN103917560B (zh) | 2011-03-28 | 2017-05-24 | 埃博灵克斯股份有限公司 | 双特异性抗‑cxcr7免疫球蛋白单可变结构域 |
| WO2012175740A1 (en) | 2011-06-23 | 2012-12-27 | Ablynx Nv | Immunoglobulin single variable domains directed against ige |
| CN106046168A (zh) | 2011-06-23 | 2016-10-26 | 埃博灵克斯股份有限公司 | 结合血清白蛋白的蛋白 |
| US20130019175A1 (en) | 2011-07-14 | 2013-01-17 | Microsoft Corporation | Submenus for context based menu system |
| EP2747783B1 (en) | 2011-09-30 | 2017-06-14 | Ablynx N.V. | Biological materials related to c-met |
| CN108200885B (zh) | 2011-10-17 | 2021-12-14 | 瑞泽恩制药公司 | 受限制的免疫球蛋白重链基因座 |
| US20130129727A1 (en) | 2011-11-17 | 2013-05-23 | Nanjingjinsirui Science & Technology Biology Corporation | Methods and systems for increasing protein stability |
| US9150648B2 (en) * | 2012-01-31 | 2015-10-06 | Regeneron Pharmaceuticals, Inc. | Anti-ASIC1 antibodies and uses thereof |
| WO2013178783A1 (en) | 2012-06-01 | 2013-12-05 | Ablynx N.V. | P2x7 receptor antagonists and agonists |
| EP2895510A2 (en) | 2012-09-13 | 2015-07-22 | Novartis AG | Single domain antibody with c-terminal modification |
| US9667316B2 (en) | 2013-05-17 | 2017-05-30 | The Boeing Company | Aircraft data transmission using phase separation |
| CN106661100A (zh) | 2014-05-16 | 2017-05-10 | 埃博灵克斯股份有限公司 | 改进的免疫球蛋白可变结构域 |
| CN108350069B (zh) | 2015-10-30 | 2021-11-12 | 埃博灵克斯股份有限公司 | 针对il-23的多肽 |
| NO2768984T3 (enExample) | 2015-11-12 | 2018-06-09 | ||
| AU2016352695B2 (en) | 2015-11-12 | 2023-07-27 | Ablynx Nv | Improved P2X7 receptor binders and polypeptides comprising the same |
| HRP20220080T1 (hr) | 2015-11-13 | 2022-04-15 | Ablynx N.V. | Poboljšane imunoglobulinske varijabilne domene koje vežu serumski albumin |
| JO3739B1 (ar) | 2015-11-18 | 2021-01-31 | Merck Sharp & Dohme | روابط ctla4 |
| AU2016357460B2 (en) | 2015-11-18 | 2023-07-27 | Ablynx Nv | Improved serum albumin binders |
| IL300122A (en) | 2015-11-18 | 2023-03-01 | Merck Sharp ַ& Dohme Llc | Substances that bind to PD1 and/or LAG3 |
| AU2016355568A1 (en) | 2015-11-18 | 2018-06-21 | Merck Sharp & Dohme Llc | PD1/CTLA4 Binders |
| KR20230165374A (ko) | 2017-01-17 | 2023-12-05 | 아블린쓰 엔.브이. | 개선된 혈청 알부민 결합제 |
| WO2021110816A1 (en) | 2019-12-06 | 2021-06-10 | Ablynx Nv | POLYPEPTIDES COMPRISING IMMUNOGLOBULIN SINGLE VARIABLE DOMAINS TARGETING TNFα AND IL-23 |
| AR120698A1 (es) | 2019-12-09 | 2022-03-09 | Ablynx Nv | Polipéptidos que comprenden dominios variables únicos de inmunoglobulina que se dirigen a il-13 y tslp |
| WO2022129572A1 (en) | 2020-12-18 | 2022-06-23 | Ablynx Nv | Polypeptides comprising immunoglobulin single variable domains targeting il-6 and tnf-alpha |
-
2015
- 2015-05-13 CN CN201580037310.3A patent/CN106661100A/zh active Pending
- 2015-05-13 CN CN201810899732.7A patent/CN109053885A/zh active Pending
- 2015-05-13 SG SG11201609162SA patent/SG11201609162SA/en unknown
- 2015-05-13 EP EP20167969.3A patent/EP3702369A1/en active Pending
- 2015-05-13 EP EP20163286.6A patent/EP3693386A1/en active Pending
- 2015-05-13 LT LTEP17178990.2T patent/LT3248986T/lt unknown
- 2015-05-13 CN CN202111040888.8A patent/CN113717280A/zh active Pending
- 2015-05-13 MX MX2016014926A patent/MX383560B/es unknown
- 2015-05-13 JP JP2017512424A patent/JP7325928B2/ja active Active
- 2015-05-13 CA CA2948076A patent/CA2948076A1/en active Pending
- 2015-05-13 HR HRP20200966TT patent/HRP20200966T1/hr unknown
- 2015-05-13 RU RU2016149463A patent/RU2746738C2/ru active
- 2015-05-13 AU AU2015261536A patent/AU2015261536B2/en active Active
- 2015-05-13 LT LTEP15722211.8T patent/LT3143042T/lt unknown
- 2015-05-13 EP EP15722211.8A patent/EP3143042B1/en active Active
- 2015-05-13 IL IL295534A patent/IL295534B2/en unknown
- 2015-05-13 HR HRP20220400TT patent/HRP20220400T1/hr unknown
- 2015-05-13 PH PH1/2016/502282A patent/PH12016502282B1/en unknown
- 2015-05-13 RS RS20220328A patent/RS63085B1/sr unknown
- 2015-05-13 KR KR1020237012493A patent/KR102769509B1/ko active Active
- 2015-05-13 IL IL299282A patent/IL299282B2/en unknown
- 2015-05-13 SG SG10201810124PA patent/SG10201810124PA/en unknown
- 2015-05-13 DK DK17178990.2T patent/DK3248986T3/da active
- 2015-05-13 HU HUE15722211A patent/HUE050007T2/hu unknown
- 2015-05-13 RS RS20201034A patent/RS60717B1/sr unknown
- 2015-05-13 WO PCT/EP2015/060643 patent/WO2015173325A2/en not_active Ceased
- 2015-05-13 PL PL17178990T patent/PL3248986T3/pl unknown
- 2015-05-13 PT PT171789902T patent/PT3248986T/pt unknown
- 2015-05-13 DK DK15722211.8T patent/DK3143042T3/da active
- 2015-05-13 NZ NZ726448A patent/NZ726448A/en unknown
- 2015-05-13 PL PL15722211T patent/PL3143042T3/pl unknown
- 2015-05-13 KR KR1020237012548A patent/KR102827683B1/ko active Active
- 2015-05-13 ES ES15722211T patent/ES2815572T3/es active Active
- 2015-05-13 ES ES17178990T patent/ES2912069T3/es active Active
- 2015-05-13 US US15/311,564 patent/US12180268B2/en active Active
- 2015-05-13 KR KR1020187022490A patent/KR20180091115A/ko not_active Ceased
- 2015-05-13 EP EP17178990.2A patent/EP3248986B1/en active Active
- 2015-05-13 CA CA3175002A patent/CA3175002A1/en active Pending
- 2015-05-13 IL IL311293A patent/IL311293B2/en unknown
- 2015-05-13 SI SI201531807T patent/SI3248986T1/sl unknown
- 2015-05-13 PT PT157222118T patent/PT3143042T/pt unknown
- 2015-05-13 KR KR1020237033317A patent/KR20230145503A/ko active Pending
- 2015-05-13 BR BR112016026773A patent/BR112016026773A2/pt not_active Application Discontinuation
- 2015-05-13 HU HUE17178990A patent/HUE058008T2/hu unknown
- 2015-05-13 BR BR122018009619-5A patent/BR122018009619B1/pt active IP Right Grant
- 2015-05-13 SI SI201531267T patent/SI3143042T1/sl unknown
- 2015-05-13 KR KR1020167035012A patent/KR20170002645A/ko not_active Ceased
- 2015-05-13 SG SG10201805288QA patent/SG10201805288QA/en unknown
-
2016
- 2016-10-31 IL IL248636A patent/IL248636B2/en unknown
- 2016-11-03 ZA ZA2016/07587A patent/ZA201607587B/en unknown
- 2016-11-14 MX MX2018007581A patent/MX2018007581A/es unknown
- 2016-11-14 MX MX2021007020A patent/MX2021007020A/es unknown
- 2016-11-14 MX MX2023010731A patent/MX2023010731A/es unknown
-
2018
- 2018-06-12 IL IL259972A patent/IL259972B/en active IP Right Grant
- 2018-06-14 AU AU2018204226A patent/AU2018204226A1/en not_active Abandoned
- 2018-06-28 JP JP2018122878A patent/JP7098439B2/ja active Active
-
2019
- 2019-11-26 US US16/695,420 patent/US11312764B2/en active Active
-
2020
- 2020-04-16 AU AU2020202570A patent/AU2020202570B2/en active Active
- 2020-04-30 AU AU2020202855A patent/AU2020202855B2/en active Active
- 2020-07-31 ZA ZA2020/04758A patent/ZA202004758B/en unknown
- 2020-07-31 ZA ZA2020/04759A patent/ZA202004759B/en unknown
- 2020-07-31 ZA ZA2020/04757A patent/ZA202004757B/en unknown
- 2020-10-01 JP JP2020167247A patent/JP7471987B2/ja active Active
- 2020-12-09 US US17/116,047 patent/US11220539B2/en active Active
-
2021
- 2021-02-03 ZA ZA2021/00742A patent/ZA202100742B/en unknown
- 2021-03-24 IL IL281755A patent/IL281755B2/en unknown
- 2021-03-29 US US17/215,039 patent/US11312765B2/en active Active
- 2021-03-29 US US17/215,121 patent/US11485777B2/en active Active
- 2021-03-29 US US17/215,163 patent/US11319364B2/en not_active Ceased
- 2021-05-24 JP JP2021087053A patent/JP7454525B2/ja active Active
- 2021-12-27 US US17/562,499 patent/US11485778B2/en active Active
-
2022
- 2022-03-17 US US17/697,508 patent/US20220332806A1/en active Pending
- 2022-03-25 US US17/704,063 patent/US20220332807A1/en active Pending
- 2022-04-13 US US17/719,496 patent/US11708404B2/en active Active
- 2022-11-28 AU AU2022279373A patent/AU2022279373A1/en active Pending
- 2022-11-28 AU AU2022279374A patent/AU2022279374A1/en active Pending
-
2024
- 2024-01-16 JP JP2024004779A patent/JP2024041939A/ja active Pending
- 2024-03-11 JP JP2024037026A patent/JP2024069377A/ja active Pending
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005092925A2 (en) | 2004-03-24 | 2005-10-06 | Xencor, Inc. | Immunoglobulin variants outside the fc region |
| JP5047950B2 (ja) | 2005-05-18 | 2012-10-10 | アブリンクス エン．ヴェー． | 腫瘍壊死因子−アルファに対する改良ナノボディ（商標） |
| JP2012500006A (ja) | 2008-08-11 | 2012-01-05 | メダレックス インコーポレーティッド | リンパ球活性化遺伝子−３（ｌａｇ−３）へ結合するヒト抗体およびその使用 |
| WO2012156219A1 (en) | 2011-05-05 | 2012-11-22 | Ablynx Nv | Amino acid sequences directed against il-17a, il-17f and/or il17-a/f and polypeptides comprising the same |
| WO2012175741A2 (en) | 2011-06-23 | 2012-12-27 | Ablynx Nv | Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains |
| WO2013024059A2 (en) | 2011-08-17 | 2013-02-21 | Glaxo Group Limited | Modified proteins and peptides |
| WO2014004427A2 (en) | 2012-06-25 | 2014-01-03 | Regeneron Pharmaceuticals, Inc. | Anti-egfr antibodies and uses thereof |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7471987B2 (ja) | 改善された免疫グロブリン可変ドメイン | |
| USRE50682E1 (en) | Immunoglobulin variable domains | |
| RU2845084C2 (ru) | Улучшенные вариабельные домены иммуноглобулина | |
| RU2809788C2 (ru) | Улучшенные вариабельные домены иммуноглобулина |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180510 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20180510 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20190416 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20190704 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190913 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20200303 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20200521 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20200722 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200828 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20210126 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210524 |
|
| C60 | Trial request (containing other claim documents, opposition documents) |
Free format text: JAPANESE INTERMEDIATE CODE: C60 Effective date: 20210524 |
|
| A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20210601 |
|
| C21 | Notice of transfer of a case for reconsideration by examiners before appeal proceedings |
Free format text: JAPANESE INTERMEDIATE CODE: C21 Effective date: 20210608 |
|
| A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20210730 |
|
| C211 | Notice of termination of reconsideration by examiners before appeal proceedings |
Free format text: JAPANESE INTERMEDIATE CODE: C211 Effective date: 20210803 |
|
| C22 | Notice of designation (change) of administrative judge |
Free format text: JAPANESE INTERMEDIATE CODE: C22 Effective date: 20220208 |
|
| C22 | Notice of designation (change) of administrative judge |
Free format text: JAPANESE INTERMEDIATE CODE: C22 Effective date: 20221011 |
|
| C13 | Notice of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: C13 Effective date: 20221122 |
|
| C302 | Record of communication |
Free format text: JAPANESE INTERMEDIATE CODE: C302 Effective date: 20221213 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20230216 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20230316 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20230411 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230519 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20230802 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7325928 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |